Feedback
Settings

Settings

Goto Application

1. WO2001055172 - ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFR$g(a) PROTEIN

PermaLink
Publication Number WO/2001/055172
Publication Date 02.08.2001
International Application No. PCT/FR2001/000253
International Filing Date 26.01.2001
Chapter 2 Demand Filed 20.08.2001
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/52 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
C07K 14/71 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
71for growth factors; for growth regulators
C07K 14/715 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
715for cytokines; for lymphokines; for interferons
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
A61P 21/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 27/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
Applicants
  • PIERRE FABRE MEDICAMENT [FR]/[FR] (AllExceptUS)
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) [FR]/[FR] (AllExceptUS)
  • ELSON, Greg [GB]/[FR] (UsOnly)
  • GAUCHAT, Jean-François [CH]/[FR] (UsOnly)
  • PLUN-FAVREAU, Hélène [FR]/[FR] (UsOnly)
  • CHEVALIER, Sylvie [FR]/[FR] (UsOnly)
  • GASCAN, Hugues [FR]/[FR] (UsOnly)
Inventors
  • ELSON, Greg
  • GAUCHAT, Jean-François
  • PLUN-FAVREAU, Hélène
  • CHEVALIER, Sylvie
  • GASCAN, Hugues
Agents
  • MARTIN, Jean-Jacques
Priority Data
00/0103527.01.2000FR
00/1308912.10.2000FR
Publication Language French (FR)
Filing Language French (FR)
Designated States
Title
(EN) ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFR$g(a) PROTEIN
(FR) COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFR$g(a)
Abstract
(EN)
The invention concerns a novel isolated complex comprising a NNT-1 protein and in addition at least a CLF-1 protein and/or a sCNTFR$g(a) protein and antibodies specifically directed against said complex. The invention further comprises a composition comprising said complex as medicine for preventing and/or treating neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease, for maintaining muscle mass in paralyzed persons, for treating obesity or cancer.
(FR)
La présente invention a pour objet un nouveau complexe isolé comprenant une protéine NNT-1 et en outre au moins une protéine CLF-1 et/ou une protéine sCNTFR$g(a) ainsi que des anticorps dirigés spécifiquement contre ledit complexe. L'invention comprend également une composition comprenant ledit complexe comme médicament pour la prévention et/ou le traitement de maladies neurodégénératives telles que la sclérose latérale amyotrophique, la maladie de Parkinson ou la maladie du Huntington, pour la maintenance de la masse musculaire chez les paralysés, pour le traitement de l'obésité ou du cancer.
Also published as
AU2001231917
Latest bibliographic data on file with the International Bureau
# -